Objectives: Triphala (TRP), a herbal extract from Tibetan medicine, has been shown to affect lymphocytes and natural killer T (NKT) cell function. We hypothesize that TRP could ameliorate bronchial hyperreactivity through immune-cell modulations.
Methods: Asthma mouse models were generated through intraperitoneal (IP) injections of ovalbumin (OVA)/2 weeks followed by repeated intranasal OVA challenges. Mice were then treated with normal saline (OVA/NS) or Triphala (OVA/TRP). Data were compared with mice treated with inhaled budesonide. All groups were assessed for allergen-induced hyperreactivity; lymphocytes from lungs, livers and spleens were analyzed for OVA-induced proliferation and their alterations were determined by flow cytometry. Oxidative reactivity using chemiluminescence, serum anti-OVA antibodies level and lung histology were assessed.
Results: Both TRP and budesonide significantly ameliorated functional and histological OVA-induced bronchial hyperreactivity. TRP had no effect on serum anti-OVA antibodies as compared with decreased levels following budesonide treatment. Furthermore, a significant increase in lung and spleen CD4 counts and a decrease in the liver were noted after TRP treatments. Bronchoalveolar fluid from TRP-treated animals but not from the budesonide-treated animals showed anti-oxidative effects.
Conclusion: TRP and budesonide caused a significant decrease in bronchial reactivity. TRP treatment altered immune-cell distributions and showed anti-oxidative properties. These findings suggest that immune-cell modulation with TRP can ameliorate lung injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1753465812452194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use and limitations of clinical data in the identification and classification of low molecular weight chemicals (LMWCs) as respiratory sensitizers: recommendations for improvement.
Crit Rev Toxicol
January 2025
Syngenta, Bracknell, United Kingdom.
While progress has been made in recent years, there are still no suitable and accepted , or models that can be used to accurately predict whether a chemical substance has the intrinsic property to cause immune-mediated chemical respiratory allergy, typically manifested as allergic asthma or allergic rhinitis which represents a severe health hazard. Regulatory authorities have relied primarily on clinical evidence (case reports, clinical databases, worker exposure studies) to classify substances as respiratory sensitizers, but this evidence can lack a proven immunological mechanism which is necessary to identify substances which can cause life-long sensitization and clinically relevant allergic symptoms in the respiratory tract in an exposed population (such respiratory allergens may be considered as "true" sensitizers, in analogy to the definition of skin sensitization, and in contrast to respiratory irritants). In light of this, the European Center for Ecotoxicology and Toxicology of Chemicals convened a Task Force to evaluate the types of clinical methods and data sources and the implications of relying on such data for regulatory decision making from a scientific perspective.
View Article and Find Full Text PDFDiagnostic Accuracy of FEF for Bronchial Hyperresponsiveness in Patients with Suspected Asthma and/or Allergic Rhinitis: A Systematic Review and Meta-analysis.
Lung
January 2025
Department of Pathology, The Second People's Hospital of China Three Gorges University/ Yichang Second People's Hospital, Yichang, 443000, Hubei, China.
Background: Some studies have suggested that the forced expiratory flow between 25 and 75% of vital capacity (FEF) can be used as an early marker of bronchial hyperresponsiveness (BHR) in asthma and allergic rhinitis (AR), but is highly variable. Here, we aimed to assess whether the FEF can be used to diagnose BHR in patients with asthma-like symptoms and AR.
Methods: PubMed, EMBASE, Web of Science, Wiley Online Library, Cochrane Library, SinoMed, CNKI, and Wanfang Data were searched to acquire eligible studies.
Circulating MicroRNAs in Idiopathic Pulmonary Fibrosis: A Narrative Review.
Curr Issues Mol Biol
December 2024
Molecular Biology Laboratory, Department of Research in Pulmonary Fibrosis, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Mexico City 14080, Mexico.
Idiopathic pulmonary fibrosis (IPF) is a chronic, deathly disease with no recognized effective cure as yet. Furthermore, its diagnosis and differentiation from other diffuse interstitial diseases remain a challenge. Circulating miRNAs have been measured in IPF and have proven to be an adequate option as biomarkers for this disease.
View Article and Find Full Text PDFSUPEROXIDE DISMUTASE (SOD2) GENE VAL16ALA POLYMORPHISM AND CHANGES IN THE VENTILATION LUNG CAPACITY OF CHILDREN - RESIDENTS OF RADIOACTIVELY CONTAMINATED TERRITORIES AND CHILDREN WHO HAVE BEEN AFFECTED BY STRESSFUL LIFE EVENTS DURING WARTIME.
Probl Radiac Med Radiobiol
December 2024
State Institution «National Scientific Center for Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine.
Objective: to determine the distribution of genotypes of genetic polymorphism of manganese superoxide dismutaseand to assess the ventilation lung capacity in children- residents of radioactively contaminated areas and childrenexposed to stressful life events during the war period.
Materials And Methods: The study involved school-age children - residents of radioactively contaminated areas(RCA) and children exposed to stressful life events during wartime. All those examined had no clinical signs of respiratory pathology.
Changing paradigms in asthma management.
Am J Med Sci
December 2024
Division of Clinical Immunology, The University of Mississippi Medical Center, Jackson, MS, USA. Electronic address:
Asthma is a complex clinical syndrome characterized by airway inflammation that can cause variable, usually reversible airway obstruction and bronchial hyperreactivity. This illness has a spectrum from intermittent to persistent that has mild, medium or severe intensity. As our understanding of the underling inflammatory pathway grows, so too does our catalogue of advanced treatments (such as monoclonal antibodies), opening the path for treatment individually curated for patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!